Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3 label. This indicates a backend/template update to the study record display without changing substantive study details.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s footer “Revision” version was updated from v3.5.2 to v3.5.3, reflecting a backend/site release rather than a change to the study record content.SummaryDifference0.1%

- Check29 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0. No visible changes to study details or page content.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded the keyword/MeSH term 'B-cell chronic lymphocytic leukemia.' Added a new resource link to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check58 days agoChange DetectedRevision tag updated to v3.5.0, replacing v3.4.3. This is a UI/version change and does not alter study details or eligibility.SummaryDifference0.1%

- Check65 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.